Payment overview · 2025
General Payments
$788.77
24 reported records · 10 companies
Healthcare provider profile · identity verified
Kitty B Carter-Wicker, MD
Allopathic & Osteopathic Physicians|Family Medicine · EAST POINT, GA · NPI 1043210974
Verified facts
What the public records show
CMS Open Payments records show Kitty B Carter-Wicker, MD received $788.77 in general payments during 2025 across 24 reported records.
GlaxoSmithKline, LLC. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $209.33 | 26.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $163.10 | 20.7% | 5 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $117.98 | 15.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $114.63 | 14.5% | 3 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $44.74 | 5.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.08 | 4.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $30.95 | 3.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.62 | 3.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $23.22 | 2.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.12 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $788.77 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $163.10 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $114.63 | 3 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $58.57 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $51.41 | 3 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $44.74 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $44.74 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.08 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $30.62 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $30.02 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.94 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 121 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 80 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 25 |
| Ezetimibe | Ezetimibe | 73 | 23 |
| Losartan Potassium | Losartan Potassium | 62 | 24 |
| Simvastatin | Simvastatin | 62 | 22 |
| Valsartan | Valsartan | 55 | 23 |
| Lovastatin | Lovastatin | 53 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 15 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Furosemide | Furosemide | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 11 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Omeprazole | Omeprazole | 28 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 27 | suppressed |
| Metformin Hcl | Metformin Hcl | 27 | 12 |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $788.77 · 24 records | GlaxoSmithKline, LLC. | APRETUDE, AREXVY, AUSTEDO XR, BENLYSTA, BEXSERO, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Fluad, Flucelvax, INFINITY, INGREZZA, OTEZLA, Ozempic, PENMENVY, REPATHA, Rybelsus, SHINGRIX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rybelsus play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error